Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Webcasts|January 7, 2026
The New Subcutaneous (SC) Landscape: Adapting Drug Delivery for Biologics Administration at Home
Author(s)Datwyler
Listen
0:00 / 0:00
Webinar Date/Time: Thu, Jan 29, 2026 9:00 AM EST
The rise of biologics is driving a massive shift: sensitive therapeutics are moving from clinic visits to Subcutaneous (SC) self-administration at home. This empowers patients and supports decentralized healthcare. Join Datwyler to explore how this trend is modifying the landscape of SC drug delivery. Learn what your system needs to succeed in the era of patient-centric care.
Register Free:
Event Overview:
The pharmaceutical industry is experiencing a profound transformation as high-value, sensitive biologics transition from requiring in-clinic intravenous (IV) infusion to convenient, at-home subcutaneous (SC) self-administration. Join Datwyler experts to analyze the forces reshaping the SC drug delivery market. Learn about critical system changes covering viscosity, volume limitations, and the role of optimized components in ensuring drug stability and patient safety.
Key Learning Objectives:
- Ensure drug safety: Learn how component selection is crucial for maintaining drug stability and minimizing risk
- Analyze the market drivers leading to the shift of biologics and sensitive therapeutics toward decentralized, home-based subcutaneous (SC) self-administration
- Discover the advantage to coengineering and how an integrated partnership model transforms complex drug delivery challenges into scalable, system-level solutions for the global market
Who Should Attend:
- Quality/regulatory personnel in parenteral drug delivery
- Formulation scientists and packaging engineers
- Device development engineers and managers
- Technical roles involving drug delivery systems
- Experts on extractables and leachables
- Procurement professionals
Speaker:
Paolo Ferrigno
Product Manager prefilled syringes and cartridges
Datwyler Healthcare
In the industry of primary parenteral packaging since 2017, Paolo Ferrigno is the product manager for prefilled syringes and cartridge components at Datwyler Healthcare. At Datwyler, Ferrigno has covered different commercial and technical roles before landing back in product management in 2022. Educated in electronics and later in marketing, Ferrigno has had a wide range of experiences spanning R&D for audio/electronics in the automotive and consumer markets and product management for B2B distribution of industrial and electronics components.
Register Free:
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.